CDK2-IN-47
CDK2-IN-47 is a potent CDK2 inhibitor with an IC50 of 0.21 μM. CDK2-IN-47 exhibits outstanding anticancer activity against MCF-7, HCT-116, and MGC-803 cell lines. CDK2-IN-47 effectively induces G1 cell cycle arrest, retinoblastoma protein (Rb) dephosphorylation, and significant apoptosis. CDK2-IN-47 can be used for the studies of breast cancer, colorectal cancer and gastric cancer[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; CDK
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Field of Research
Cancer
Smiles
O=C1C(C)=CN(CC(N[C@H](CC(C)C)C(OC)=O)=O)C2=NC(SC)=NN12
Molecular Formula
C16H23N5O4S
Molecular Weight
381.45
References & Citations
[1]Nagy IM, et al. Design, synthesis, biological and computational evaluation of novel S/N-glycerolyl and peptide-conjugated [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potent CDK2 inhibitors for anticancer therapy. Bioorg Chem. 2025 Sep 2;165:108952.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK1; CDK2; CDK4; CDK6; CDK7; CDK9
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
